Baxter cuts FY25 adjusted EPS view to $2.42-$2.52 from $2.47-$2.55

Consensus $2.52. The company said, “Baxter (BAX) now expects sales growth from continuing operations of 6% to 7% on a reported basis. On an operational basis, Baxter expects sales growth of 3% to 4%. The company now expects adjusted earnings from continuing operations, before special items, of $2.42 to $2.52 per diluted share. Baxter’s updated guidance attempts to capture potential downside risks associated with factors primarily impacting the company’s Medical Products & Therapies segment.”